Immunovant Inc. (IMVT)$34.15

Market Cap: 2.59 BCurrency: USD

Research Snapshot

Static fundamentals, valuation context, and investor signals for Immunovant Inc. (IMVT).

HEALTHCARE

BIOTECHNOLOGY

DCF ready

Valuation

-4.1x

EV/FCF, N/A FCF yield

Quality

-59.3%

ROIC, N/A FCF margin

Growth

N/A

5Y sales (revenue) CAGR

Balance sheet

0.0x

Debt/equity, 9.1x current ratio

Superinvestors

Top: David Einhorn (0.1%)

Strengths to research

Debt/equity looks manageable at 0.0x.
8 annual periods are available for trend analysis.

Watchouts

No major valuation, balance sheet, or growth watchouts were detected by the static screen.

Annual data: 8 periods

Quarterly data: 24 periods

Stock snapshot: May 25, 2026

Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for IMVT.

Grade F

/ 100

Peer Comparison

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best


IMVT Target	Immunovant Inc.	$2.6B	-12.3x	-4.1x	-59.3%	N/A	N/A	N/A	N/A	N/A
NAMS	Newamsterdam Pharma Co Nv	$2.2B	-20.6x	-11.7x	-29.7%	N/A	-657.8%	N/A	N/A	N/A
TVTX	Travere Therapeutics Inc.	$1.9B	-153.2x	47.9x	-22.2%	19.9%	7.7%	N/A	N/A	N/A
EWTX	Edgewise Therapeutics Inc.	$1.7B	-20.1x	-11.6x	-0.0%	N/A	N/A	N/A	N/A	N/A
ADPT	Adaptive Biotechnologies Corp.	$1.5B	-35.6x	-29.7x	-27.2%	23.0%	-17.7%	N/A	N/A	N/A
PCVX	Vaxcyte Inc.	$4.4B	-8.4x	-6.3x	-0.0%	N/A	N/A	N/A	N/A	N/A
MESO	Mesoblast Ltd Spon ADR	$1.4B	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IONS	Ionis Pharmaceuticals Inc.	$5.4B	-31.7x	-21.2x	-16.6%	5.3%	-33.9%	N/A	N/A	N/A
AXSM	Axsome Therapeutics Inc.	$5.7B	-64.1x	-57.1x	-207.5%	N/A	-14.7%	N/A	N/A	N/A

Financial Charts

No financial data available for IMVT (annual).

1 superinvestors own IMVT

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership

Fund	Shares	Value	% Portfolio	QoQ Change
David Einhorn Greenlight Capital	93,520	$2M	0.07%	0.0%